Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | FABP3 | P05413 | 1/20 | 0.30 |
| ▸ | FABP4 | P15090 | 1/20 | 0.30 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19053628 | 0.82 | IDO1 (0.32) | GABRA1GABRB2GABRB1 | |
| SCHEMBL84481 | 0.82 | CES2 (0.39) | GABRA1GABRB2ALDH1A1GAAALOX12 | |
| SCHEMBL22288163 | 0.82 | GABRA1 (0.46) | GABRA1GABRB2GABRB1ALDH1A1GAA | |
| SCHEMBL12248241 | 0.82 | GABRA1 (0.37) | GABRA1GABRB2ALDH1A1GAAALOX12 | |
| SCHEMBL18100443 | 0.82 | GABRA1 (0.46) | GABRA1GABRB2GABRB1ALDH1A1GAA | |
| SCHEMBL28135552 | 0.79 | GABRA1 (0.36) | GABRA1GABRB2ALDH1A1GAAALOX12 | |
| SCHEMBL23794588 | 0.78 | CES2 (0.30) | — | |
| SCHEMBL16692509 | 0.77 | ABCB11 (0.35) | GABRA1GABRB2GABRB1 | |
| SCHEMBL25833306 | 0.74 | AOC3 (0.31) | — | |
| SCHEMBL8215364 | 0.73 | GABRA1 (0.39) | GABRA1GABRB2GABRB1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322666-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-10-24 | — | — | US | disclosed |
| US-20180099967-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099967-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-04-12 | — | — | US | disclosed |
| US-20170190701-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2017-07-06 | — | — | US | disclosed |
| US-20170190701-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099967-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | TYMS, CCNI, TYMP | GABRA1 3793/4885GABRB2 3937/4885GABRB1 3598/4885 |
| US-20190322666-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | TYMS, CCNI, TYMP | GABRA1 3793/4885GABRB2 3937/4885GABRB1 3598/4885 |
| US-20170190701-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | TYMS, CCNI, TYMP | GABRA1 3793/4885GABRB2 3937/4885GABRB1 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.